Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xingnaojing for Acute Ischemic Stroke (XMAS)
NCT02728180Phase 4Unknown
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Mar 2016
- Primary completion
- Dec 2019
- Modality
- HM (Herbal Medicine), Combination Drug
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Xingnaojing injection in ischemic stroke (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Proportion of patients independent at 90 days. Status: unknown.
02
Drugs
Xingnaojing injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02728180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728180.